Prostatic Neoplasms, Castration-Resistant Clinical Trial
Official title:
URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra-223 Dichloride Treated mCRPC Patients in a Real Life Setting in Germany.
This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03325127 -
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
|
||
| Withdrawn |
NCT02906605 -
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05743621 -
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02204072 -
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1 | |
| Recruiting |
NCT05393791 -
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
|
Phase 2 | |
| Completed |
NCT03927391 -
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
|
Phase 4 | |
| Recruiting |
NCT06353386 -
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03431350 -
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03822845 -
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT02162836 -
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02899104 -
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
|
||
| Active, not recruiting |
NCT04381832 -
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03563014 -
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
|
||
| Active, not recruiting |
NCT05968599 -
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
|
||
| Active, not recruiting |
NCT02803437 -
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
|
||
| Recruiting |
NCT05944237 -
HTL0039732 in Participants With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03173859 -
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
|
Phase 2 | |
| Terminated |
NCT02057666 -
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04717154 -
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
|
Phase 2 |